Jeffrey Farrow joins Lisata Therapeutics Board and Audit Committee
1 report, 1 independent
Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lisata Therapeutics, Inc. announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026. Mr. Farrow will also serve on the company's Audit Committee. The Board determined that Mr. Farrow is independent under Nasdaq listing rules.
From manilatimes.net
Why it matters
The appointment brings financial leadership experience to Lisata Therapeutics, Inc. as the company advances its Phase 2b programs in severe hypertriglyceridemia and acromegaly. Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc.
From manilatimes.net
Who's involved
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Jeff
Russian singer
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
-
Horizon Therapeutics
Irish tax-registered pharmaceutical
Nothing else this week.